Xvivo Perfusion develops medical technology for organ preservation and evaluation outside the body before transplant. Its systems and solutions support lung, heart and kidney transplantation by enabling machine perfusion and assessment of donor organs. The company serves transplant centers and hospitals that need tools to expand usable organ supply and improve transplant logistics and outcomes.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 227.6 | — | 36.4 | -57.4% |
| Q1 2025 | 218.6 | — | -12.4 | -152.5% |
| Q2 2025 | 178.3 | — | 1.6 | -94.2% |
| Q4 2025 | 226.1 | -0.6% | 31.6 | -13% |
| Q1 2026 | 241 | 10.2% | 36.3 | — |
| Q2 2026 | 239 | 34% | 16.3 | 935.1% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Dynavox Group AB (publ) (DYVOX), Synsam AB (publ) (SYNSAM), Sivers Semiconductors AB (publ) (SIVE), Apotea AB (publ) (APOTEA), Yubico AB (YUBICO), Hemnet Group AB (publ) (HEM)